PMA device
Sof-Sensor
Medtronic Minimed · Sensor, Glucose, Invasive (MDS, Class III) · First FDA decision Nov 12, 2015, newest Nov 12, 2015Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
4
Naming "Sof-Sensor"
MAUDE reports
0
Brand "Sof-Sensor", since 2015
PubMed studies
9
Mentioning "Sof-Sensor"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Sof-Sensor
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- SOF-SENSORPMA supplement
P980022-S159 · Decided Nov 12, 2015 · 489 days after receipt · Normal 180 Day Track
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Sof-Sensor", any status and sponsor, newest update first.
University of Ljubljana, Faculty of MedicineAcademic, hospital or other
NCT02657083 · 20 participants · Start Jan 2016 · Primary completion Jun 2016
Device: DreaMed Substance Administration Device; Sensor Augmented Pump (SAP) · For: Type 1 Diabetes Mellitus
Sites: Ljubljana, Slovenia
Endocrinology Research Centre, MoscowGovernment (non-federal)
NCT02423993 · 77 participants · Start Oct 2009 · Primary completion Oct 2012
Device: CSII; CGM-RT · For: Diabetes Mellitus, Type 1
Medical University of GrazAcademic, hospital or other
NCT02359617 · 10 participants · Start Feb 2013 · Primary completion Oct 2014
Device: glucose sensing · For: Type 1 Diabetes
Sites: Graz, Austria
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Sof-Sensor", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MDS
232,139 reports: 226,671 malfunction, 5,201 injury, 215 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Paradigm REAL-Time Insulin Pump (MMT-522, MMT-722)Open, Classified
Z-1749-2026 · Started Feb 13, 2026 · Posted by FDA Apr 2, 2026
Reason given: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and...
Cause as FDA categorized it: Device Design · Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
- Paradigm REAL-Time Revel Insulin Pump (MMT-523, MMT-723)Open, Classified
Z-1750-2026 · Started Feb 13, 2026 · Posted by FDA Apr 2, 2026
Reason given: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and...
Cause as FDA categorized it: Device Design · Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
Z-1256-2025 · Started Jan 31, 2025 · Posted by FDA Mar 3, 2025
Reason given: All Medtronic MiniMed pumps (Paradigm series, Minimed 530G, 6XX series, and 7XX series) were found to have the potential for abnormal insulin delivery due to changes in air pressure, which can be found during airplane take-off or landing. An unexpected additional dose of insulin, which can occur during take-off, can...
Cause as FDA categorized it: Device Design · Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
11 more recall records with a free account
Published research
The most relevant PubMed records for "Sof-Sensor"[tiab]. The summary above synthesizes these.
- Accuracy of the Sof-sensor glucose sensor with the iPro calibration algorithm.
Welsh JB, Kaufman FR, Lee SW · J Diabetes Sci Technol · 2012Evaluation Study, Letter
- Continuous Glucose Monitor Interference With Commonly Prescribed Medications: A Pilot Study.
Basu A, Slama MQ, Nicholson WT, et al. · J Diabetes Sci Technol · 2017Clinical Trial, Research Support, Non-U.S. Gov't
- Feasibility of adjacent insulin infusion and continuous glucose monitoring via the Medtronic Combo-Set.
O'Neal DN, Adhya S, Jenkins A, et al. · J Diabetes Sci Technol · 2013Clinical Trial, Research Support, Non-U.S. Gov't
- Porous, Dexamethasone-loaded polyurethane coatings extend performance window of implantable glucose sensors in vivo.
Vallejo-Heligon SG, Brown NL, Reichert WM, et al. · Acta Biomater · 2016Research Support, N.I.H., Extramural
- Analysis: accuracy performance of the Medtronic NexSensor for 6 days in an inpatient setting using abdomen and buttocks insertion sites.
Glandt M, Raz I · J Diabetes Sci Technol · 2011Comment
- Comparison of the pharmacodynamics of protamine zinc insulin and insulin degludec and validation of the continuous glucose monitoring system iPro2 in healthy cats.
Salesov E, Zini E, Riederer A, et al. · Res Vet Sci · 2018Comparative Study
- Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia.
Buckingham BA, Cameron F, Calhoun P, et al. · Diabetes Technol Ther · 2013Comparative Study, Multicenter Study
- Nocturnal continuous glucose monitoring: accuracy and reliability of hypoglycemia detection in patients with type 1 diabetes at high risk of severe hypoglycemia.
Bay C, Kristensen PL, Pedersen-Bjergaard U, et al. · Diabetes Technol Ther · 2013Multicenter Study, Randomized Controlled Trial
- Performance comparison of the medtronic sof-sensor and enlite glucose sensors in inpatient studies of individuals with type 1 diabetes.
Calhoun P, Lum J, Beck RW, et al. · Diabetes Technol Ther · 2013Comparative Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code MDS.
- Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2018
- G5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2024
- FreeStyle Libre Pro Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · PMA 2020
- Freestyle Navigator Continuous Glucose Monitoring SystemAbbott Laboratories · PMA 2011
- Paradigm Real-Time Insulin PumpMedtronic Minimed · PMA 2015
- Medtronic Minimed Continuous Glucose Monitoring SystemMedtronic Minimed · PMA 2011
- Guardian Connect SystemMedtronic Minimed · PMA 2025
- Dexcom Seven SystemDexcom, Inc. · PMA 2009
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.